Early Heart Protection • Inherited Lipid RiskPANEL-CVD-28

Cardiovascular & Cardiometabolic Panel

Over 50% of premature cardiovascular events have an underlying hereditary component. This panel examines genes linked to Familial Hypercholesterolemia (FH), hypertrophic and dilated cardiomyopathies, thoracic aortic aneurysms, and cardiac channelopathies—giving your physician the clinical data necessary to protect your cardiovascular health proactively.

Cardio Genes28 Targets

Accuracy99.9%

Turnaround Time7–10 Days

MethodCheek Swab

Check If You Qualify

Takes under 2 minutes • Quick Pre-Qualification

Check Eligibility →

HIPAA 256-Bit Encrypted

Who Should Consider This Screening?

Healthcare providers recommend this diagnostic panel for individuals with the following personal or family health indicators:

Immediate family member suffered a heart attack or stroke before age 55 (men) or 65 (women).

Persistent LDL cholesterol > 190 mg/dL unresponsive to standard lifestyle changes.

Personal diagnosis or family history of unexplained cardiac arrhythmia, syncope (fainting), or cardiomyopathy.

Family history of aortic aneurysm or sudden unexplained cardiac death in young relatives.

Biomarkers & Genes Evaluated in this Panel

Processed using high-complexity Next-Generation Sequencing (NGS) in CLIA-certified and CAP-accredited partner laboratories.

Gene Symbol / Name	Clinical Significance	Actionable Impact
LDLR, APOB, PCSK9Familial Hypercholesterolemia Clearance Trio	Regulates LDL cholesterol uptake and lifelong arterial plaque accumulation rates.	Qualifies patients for high-potency statins or advanced PCSK9 inhibitor therapies to dramatically lower cardiac event risks.
MYH7 & MYBPC3Cardiac Sarcomere Structural Proteins	Primary genetic drivers of hypertrophic and dilated cardiomyopathy.	Directs regular echocardiograms, Holter monitoring, and personalized exercise/exertion safety boundaries.
KCNQ1 & SCN5ACardiac Ion Channel Conductors	Linked to Long QT Syndrome, Brugada syndrome, and familial arrhythmia predispositions.	Prevents sudden cardiac events by avoiding contraindicated QT-prolonging medications and guiding beta-blocker therapy.

Sample Report & Diagnostic Action Plan

Every patient receives an easy-to-understand diagnostic summary and a detailed clinical report tailored for their primary care doctor.

Sample Result ClassificationPathogenic Variant Identified

Identified Finding:

Pathogenic variant detected in LDLR (c.1775G>A, p.Gly592Glu) consistent with Familial Hypercholesterolemia.

Clinician Recommendation:

Recommend intensive lipid-lowering therapy, baseline coronary artery calcium (CAC) scan, and cascade screening for first-degree family members.

Clinical Care & Laboratory Standards

How our licensed physician network and accredited laboratories deliver personalized diagnostic clarity to your doorstep:

100% Physician-Ordered & CLIA Lab Certified

Physician-ordered cardiovascular genomic analysis evaluates 28 cardiac biomarkers to identify inherited risks for familial hypercholesterolemia, cardiomyopathies, and early-onset vascular events.

Our network of state-licensed physicians reviews your clinical indications to confirm medical necessity and coordinate care before any kit is mailed.

Physician-Ordered Clinical Screening

Ready to Check Your Eligibility for Cardiovascular & Cardiometabolic Panel?

Takes under 2 minutes • Painless at-home cheek swab • 100% Physician Reviewed

Start 2-Minute Pre-Qualification →